Cardax, Inc.
CDXI
Rank in Stocks
#35293
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and... Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$80.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cardax, Inc. (CDXI)
Category
Healthcare
Operating Margin for Cardax, Inc. (CDXI)
Operating Margin as of November 2026 TTM: -568.26%
According to Cardax, Inc.'s latest financial reports, its current operating margin (TTM) is -568.26%. At the end of 2020 the company had an operating margin of -568.26%.
Operating Margin history for Cardax, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -568.26% | 0.00% |
| 2020 | -568.26% | -0.91% |
| 2019 | -573.47% | 115.40% |
| 2018 | -266.24% | -18.85% |
| 2017 | -328.07% | -93.68% |
| 2016 | -5,190.95% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -86.47% | 545.78% |
| 2012 | -13.39% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.07% |
US
|
|
| -149.01% | -99.74% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cardax, Inc.'s operating margin
What is Cardax, Inc.'s operating margin?
Cardax, Inc.'s operating margin is -568.26%, as of Nov 2026.
What was Cardax, Inc.'s operating margin in 2020?
In 2020, Cardax, Inc.'s operating margin was -568.26%, compared with -573.47% in 2019.
How has Cardax, Inc.'s operating margin changed since 2015?
From 2015 to 2020, Cardax, Inc.'s operating margin was highest in 2015 (0.00%) and lowest in 2016 (-5,190.95%).
How does Cardax, Inc.'s operating margin compare with similar companies?
Cardax, Inc.'s operating margin (-568.26%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.